Draft National Health Research Policy 2026: Key Features and Impact

#GS-2 #GS-3 #Governance & Social Justice #Health #Education #Science & Technology #Artificial Intelligence #National

Why in News

The Department of Health Research (DHR) under the Ministry of Health and Family Welfare recently released the Draft National Health Research Policy 2026 for public feedback.
This draft represents India's first unified framework designed to bridge biomedical science, clinical medicine, public health, epidemiology, digital health, and artificial intelligence.
It aims to align scientific research across the country directly with real disease burdens and public health priorities.

The policy proposes setting up the National Health Research Agenda (NHRA) to set research priorities based on disease burden, health equity, pandemic readiness, and strategic national goals.
It establishes a three-tier governance model: the National Health Research Stewardship Committee for strategy, the Department of Health Research (DHR) for execution, and the Indian Council of Medical Research (ICMR) for technical leadership.
It moves away from evaluation based only on papers and patents, opting instead for real-world impact measured by the ICMR Impact of Research and Innovation Scale (ICMR-IRIS) introduced in 2025.
India currently spends just 0.024% of GDP on health research, so the policy proposes raising public spending to 0.072% by 2037 and 0.15% by 2047.
It targets key emerging areas such as artificial intelligence (AI), health data science, cell therapy, gene therapy, precision medicine, and climate health alongside traditional diseases like Tuberculosis and Antimicrobial Resistance.
Publicly funded research infrastructure will operate as a shared national resource to expand access across all institutions and reduce red tape.
The policy emphasizes research integrity, data safety, cybersecurity, and public trust to build an open and accountable research system.

Health research in India remains scattered across bodies like ICMR, Department of Biotechnology (DBT), CSIR, AIIMS, and state medical universities, causing duplicated effort and slow policy translation.
Top institutions like ICMR and AIIMS hold most research capacity, while Tier-II and Tier-III medical colleges lack essential infrastructure and scientific personnel.
Current research priorities often miss India's actual health shifts, where infectious diseases, Non-Communicable Diseases (NCDs), and climate-sensitive illnesses occur at the same time.
A system focused strictly on journal papers creates a gap where scientific findings rarely become affordable local treatments or practical public policy.
Rapid growth in Artificial Intelligence (AI), genomics, precision medicine, and digital health tools has moved faster than current regulatory processes.
India ranked 66th out of 195 nations in the Global Health Security Index (2021), showing a clear need for stronger local disease surveillance and pandemic preparedness.
Scientific credibility has suffered due to poor practices like fake data, plagiarism, peer-review fraud, weak oversight, and manipulative citations.

The ICMR runs the National Health Research Programme (NHRP), offering funding up to Rs 25 crore per project for major health issues like Tuberculosis and Cancer.
The ICMR introduced specialized grants such as the First in the World Challenge (FIWC), Anveshan Grants, and Nischayak Grants to encourage early innovation and local medical technology.
The DHR manages the Human Resource Development (HRD) Scheme using Women Scientist Fellowships, Start-up Grants, and NRI/OCI Fellowships to build a skilled workforce.
The government is building Multi-Disciplinary Research Units (MRUs) in medical colleges, Model Rural Health Research Units (MRHRUs), and a nation-wide network of Viral Research and Diagnostic Laboratories (VRDLs).
The Anusandhan National Research Foundation (ANRF) was created to promote research culture and fund innovation across the country.
In 2026, ISRO and AIIMS signed an agreement to advance space medicine and create medical protocols for long space flights, including the Bharatiya Antariksh Station.

India needs to shift its focus from being a manufacturing hub for generic medicines to becoming a global leader in discovering novel treatments.
The government must properly deploy the Rs 1 lakh crore ANRF fund and simplify clinical trial approvals managed by the CDSCO.
Building a cooperative model between Government, Academia, and Industry will help India secure long-term independence in healthcare.